Pathological characteristics of patients who develop hepatocellular carcinoma with negative results of both serous hepatitis B surface antigen and hepatitis C virus antibody

Hepatology Research

Volumn 44, Issue 11, 2014, Pages 1039-1046

  Kondo, Reiichiro ^a,b   Nakashima, Osamu ^b   Sata, Michio ^a   Imazeki, Fumio ^c   Yokosuka, Osamu ^c   Tanikawa, Ken ^b   Kage, Masayoshi ^a,b   Yano, Hirohisa ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Diabetes mellitus; Hepatocellular carcinoma; Large liver cell change; Non alcoholic steatohepatitis; Non B non C; Occult hepatitis B infection

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

AGED; ALCOHOL ABUSE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CANCER PATIENT; CANCER TISSUE; CHRONIC HEPATITIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GENOME ANALYSIS; HEPATITIS; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; LIVER TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); VIRUS GENOME;

EID: 84914158665     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12219     Document Type: Article

References (30)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-1763.
3. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832.
4. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969-974.
5. Kiyosawa K, Sodeyama T, Tanaka E etal. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-675.
6. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372-1380.
7. Taura N, Fukushima N, Yatsuhashi H etal. The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. Med Sci Monit 2010; 17: 7-11.
8. Abe H, Yoshizawa K, Kitahara T, Aizawa R, Matsuoka M, Aizawa Y. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol 2008; 43: 967-974.
9. Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 2006; 25: 3771-3777.
10. Haddow JE, Palomaki GE, McClain M, Craig W. Hereditary haemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention. J Med Screen 2003; 10: 11-13.
11. Moucari R, Rautou PE, Cazals-Hatem D etal. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut 2008; 57: 828-835.
12. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-1354.
13. Yasui K, Hasimoto E, Komorizono Y etal. Charactaristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 428-433.
14. Ludwig J. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology 1993; 105: 274-278.
15. Chang MH, Chen CJ, Lai MS etal. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336: 1855-1859.
16. Nishiguchi S, Kuroki T, Nakatani S etal. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
17. Nishiguchi S, Tamori A, Kudo S. Effects of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48: 71-75.
18. Kawaguchi T, Kakuma T, Yatsuhashi H etal. Date mining reveals complex interactions of risk factors and clinical feature profiling associated with the staging of non-hepatitis B virus/non-hepatitis C virus-related hepatocellilar carcinoma. Hepatol Res 2011; 41: 564-571.
19. Yano Y, Yamashita F, Sumie S etal. Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antiboby but positive for anti-HBc antibody in Japan. Am J Gastroenterol 2002; 97: 156-161.
20. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol 2003; 38 (Suppl 1): S38-53.
21. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218.
22. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
23. Crawford JM. Pathological assessment of liver cell dysplasia and benign liver tumors: differentiation from malignant tumors. Semin Diagn Pathol 1990; 7: 115-128.
24. Park YN, Roncalli M. Large liver cell dysplasia: a controversial entity. J Hepatol 2006; 45: 734-743.
25. Paradis V, Laurendeau I, Vidaud M, Bedossa P. Clonal analysis of macronodules in cirrhosis. Hepatology 1998; 28: 953-958.
26. Libbrecht L, Craninx M, Nevens F, Desmet V, Roskams T. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 2001; 39: 66-73.
27. Kim H, Oh BK, Roncalli M etal. Large liver cell change in hepatitis B virus-related liver cirrhosis. Hepatology 2009; 50: 752-762.
28. Feitelson MA, Duan LX. Hepatitis B virus x antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am J Pathol 1997; 150: 1141-1157.
29. Shiota G, Oyama K, Udagawa A etal. Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53. J Med Virol 2000; 61: 151-158.
30. Tamori A, Nishiguchi S, Kudo S etal. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J Med Virol 2003; 71: 492-498.